• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by ATI Physical Therapy Inc.

    6/26/23 4:31:55 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care
    Get the next $ATIP alert in real time by email
    SC 13D 1 dp195751_sc13d.htm FORM SC 13D

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    _____________________

     

    Schedule 13D

     


    Under the Securities Exchange Act of 1934

     

    ATI Physical Therapy, Inc.

    (Name of Issuer)

     

    Class A Common Stock, par value $0.0001 per share
    (Title of Class of Securities)
     
    00216W208
    (CUSIP Number)
     

    Andrea E. Daly, Esq.

    c/o Onex Corporation
    161 Bay Street P.O. Box 700

    Toronto, ON, Canada, M5J 2S1
    +1 (416) 362-7711

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
     
     
    June 15, 2023
     
    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-l(e), 240.13d-l(f) or 240.13d-l(g), check the following box.

    _____________________

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

    _____________________

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 00216W208

     

    1. Names of Reporting Persons
    Onex Corporation
    2. Check The Appropriate Box if a Member of a Group (See Instructions)
    (a) (b)
    3. SEC Use Only
    4. Source of funds (see instructions)
    OO
    5. Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
    6. Citizenship or Place of Organization
    Ontario, Canada
    Number of Shares Beneficially Owned By Each Reporting Person With 7. Sole Voting Power
    0
    8. Shared Voting Power
    758,040(1)
    9. Sole Dispositive Power
    0
    10. Shared Dispositive Power
    758,040 (1)
    11. Aggregate Amount Beneficially Owned by Each Reporting Person
    758,040(1)
    12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
    13. Percent of Class Represented By Amount in Row (11)
    15.4%(2)
    14. Type of Reporting Person (See Instructions)
    CO
           
    (1)Represents 758,040 shares of Class A Common Stock, par value $0.0001 per share (“Class A Common Stock”), including (i) 13,240 shares of Class A Common Stock issuable upon exercise of warrants to acquire shares of Class A Common Stock upon payment of $150.00 per share (“Series I Warrants”), (ii) 14,634 shares of Class A Common Stock issuable upon exercise of warrants to acquire shares of Class A Common Stock upon payment of $0.50 per share (“Series II Warrants”) and (iii) 730,166 shares of Class A Common Stock issuable upon conversion of second lien PIK convertible notes (“Notes”).

     

    (2)Calculated based on (i) 4,169,911 shares of Class A Common Stock issued and outstanding as of April 17, 2023, as reported by the Issuer in its Current Report on Form 8-K, filed on June 13, 2023 (as adjusted for the 1-for-50 reverse stock split of the Company, effective as of June 14, 2023, as reported by the Issuer in its Current Report on Form 8-K, filed on June 14, 2023 (the “Reverse Stock Split”)), (ii) 27,874 shares of Class A Common Stock issuable in connection with the Series I Warrants and Series II Warrants and (iii) 730,166 shares of Class A Common Stock issuable upon conversion of Notes.

     

     

     

    CUSIP No. 00216W208

     

    1. Names of Reporting Persons
    OMI Partnership Holdings Ltd.
    2. Check The Appropriate Box if a Member of a Group (See Instructions)
    (a) (b)
    3. SEC Use Only
    4. Source of funds (see instructions)
    OO
    5. Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
    6. Citizenship or Place of Organization
    Ontario, Canada
    Number of Shares Beneficially Owned By Each Reporting Person With 7. Sole Voting Power
    0
    8. Shared Voting Power
    758,040(1)
    9. Sole Dispositive Power
    0
    10. Shared Dispositive Power
    758,040(1)
    11. Aggregate Amount Beneficially Owned by Each Reporting Person
    758,040(1)
    12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
    13. Percent of Class Represented By Amount in Row (11)
    15.4%(2)
    14. Type of Reporting Person (See Instructions)
    OO
           
    (1)Represents 758,040 shares of Class A Common Stock, including (i) 13,240 shares of Class A Common Stock issuable upon exercise of Series I Warrants, (ii) 14,634 shares of Class A Common Stock issuable upon exercise of Series II Warrants and (iii) 730,166 shares of Class A Common Stock issuable upon conversion of Notes.

     

    (2)Calculated based on (i) 4,169,911 shares of Class A Common Stock issued and outstanding as of April 17, 2023, as reported by the Issuer in its Current Report on Form 8-K, filed on June 13, 2023 (as adjusted for the Reverse Stock Split), (ii) 27,874 shares of Class A Common Stock issuable in connection with the Series I Warrants and Series II Warrants and (iii) 730,166 shares of Class A Common Stock issuable upon conversion of Notes.

     

     

     

    CUSIP No. 00216W208

     

    1. Names of Reporting Persons
    Onex Capital Solutions GP, LLC
    2. Check The Appropriate Box if a Member of a Group (See Instructions)
    (a) (b)
    3. SEC Use Only
    4. Source of funds (see instructions)
    OO
    5. Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
    6. Citizenship or Place of Organization
    Delaware
    Number of Shares Beneficially Owned By Each Reporting Person With 7. Sole Voting Power
    0
    8. Shared Voting Power
    758,040(1)
    9. Sole Dispositive Power
    0
    10. Shared Dispositive Power
    758,040(1)
    11. Aggregate Amount Beneficially Owned by Each Reporting Person
    758,040(1)
    12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
    13. Percent of Class Represented By Amount in Row (11)
    15.4%(2)
    14. Type of Reporting Person (See Instructions)
    OO
           
    (1)Represents 758,040 shares of Class A Common Stock, including (i) 13,240 shares of Class A Common Stock issuable upon exercise of Series I Warrants, (ii) 14,634 shares of Class A Common Stock issuable upon exercise of Series II Warrants and (iii) 730,166 shares of Class A Common Stock issuable upon conversion of Notes.

     

    (2)Calculated based on (i) 4,169,911 shares of Class A Common Stock issued and outstanding as of April 17, 2023, as reported by the Issuer in its Current Report on Form 8-K, filed on June 13, 2023 (as adjusted for the Reverse Stock Split), (ii) 27,874 shares of Class A Common Stock issuable in connection with the Series I Warrants and Series II Warrants and (iii) 730,166 shares of Class A Common Stock issuable upon conversion of Notes.

     

     

     

    CUSIP No. 00216W208

     

    1. Names of Reporting Persons
    Onex Capital Solutions GP, LP
    2. Check The Appropriate Box if a Member of a Group (See Instructions)
    (a) (b)
    3. SEC Use Only
    4. Source of funds (see instructions)
    OO
    5. Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
    6. Citizenship or Place of Organization
    Delaware
    Number of Shares Beneficially Owned By Each Reporting Person With 7. Sole Voting Power
    0
    8. Shared Voting Power
    758,040 (1)
    9. Sole Dispositive Power
    0
    10. Shared Dispositive Power
    758,040 (1)
    11. Aggregate Amount Beneficially Owned by Each Reporting Person
    758,040 (1)
    12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
    13. Percent of Class Represented By Amount in Row (11)
    15.4%(2)
    14. Type of Reporting Person (See Instructions)
    PN
           
    (1)Represents 758,040 shares of Class A Common Stock, including (i) 13,240 shares of Class A Common Stock issuable upon exercise of Series I Warrants, (ii) 14,634 shares of Class A Common Stock issuable upon exercise of Series II Warrants and (iii) 730,166 shares of Class A Common Stock issuable upon conversion of Notes.

     

    (2)Calculated based on (i) 4,169,911 shares of Class A Common Stock issued and outstanding as of April 17, 2023, as reported by the Issuer in its Current Report on Form 8-K, filed on June 13, 2023 (as adjusted for the Reverse Stock Split), (ii) 27,874 shares of Class A Common Stock issuable in connection with the Series I Warrants and Series II Warrants and (iii) 730,166 shares of Class A Common Stock issuable upon conversion of Notes.

     

     

     

    CUSIP No. 00216W208

     

    1. Names of Reporting Persons
    Onex Capital Solutions Holdings, LP
    2. Check The Appropriate Box if a Member of a Group (See Instructions)
    (a) (b)
    3. SEC Use Only
    4. Source of funds (see instructions)
    WC, OO
    5. Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
    6. Citizenship or Place of Organization
    Delaware
    Number of Shares Beneficially Owned By Each Reporting Person With 7. Sole Voting Power
    0
    8. Shared Voting Power
    758,040(1)
    9. Sole Dispositive Power
    0
    10. Shared Dispositive Power
    758,040(1)
    11. Aggregate Amount Beneficially Owned by Each Reporting Person
    758,040 (1)
    12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
    13. Percent of Class Represented By Amount in Row (11)
    15.4%(2)
    14. Type of Reporting Person (See Instructions)
    PN
           
    (1)Represents 758,040 shares of Class A Common Stock, including (i) 13,240 shares of Class A Common Stock issuable upon exercise of Series I Warrants, (ii) 14,634 shares of Class A Common Stock issuable upon exercise of Series II Warrants and (iii) 730,166 shares of Class A Common Stock issuable upon conversion of Notes.

     

    (2)Calculated based on (i) 4,169,911 shares of Class A Common Stock issued and outstanding as of April 17, 2023, as reported by the Issuer in its Current Report on Form 8-K, filed on June 13, 2023 (as adjusted for the Reverse Stock Split), (ii) 27,874 shares of Class A Common Stock issuable in connection with the Series I Warrants and Series II Warrants and (iii) 730,166 shares of Class A Common Stock issuable upon conversion of Notes.

     

     

     

    CUSIP No. 00216W208

     

    1. Names of Reporting Persons
    Gerald W. Schwartz
    2. Check The Appropriate Box if a Member of a Group (See Instructions)
    (a) (b)
    3. SEC Use Only
    4. Source of funds (see instructions)
    OO
    5. Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
    6. Citizenship or Place of Organization
    Canada
    Number of Shares Beneficially Owned By Each Reporting Person With 7. Sole Voting Power
    0
    8. Shared Voting Power
    758,040(1)
    9. Sole Dispositive Power
    0
    10. Shared Dispositive Power
    758,040(1)
    11. Aggregate Amount Beneficially Owned by Each Reporting Person
    758,040(1)
    12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
    13. Percent of Class Represented By Amount in Row (11)
    15.4%(2)
    14.

    Type of Reporting Person (See Instructions)

    IN

           
    (1)Represents 758,040 shares of Class A Common Stock, including (i) 13,240 shares of Class A Common Stock issuable upon exercise of Series I Warrants, (ii) 14,634 shares of Class A Common Stock issuable upon exercise of Series II Warrants and (iii) 730,166 shares of Class A Common Stock issuable upon conversion of Notes.

     

    (2)Calculated based on (i) 4,169,911 shares of Class A Common Stock issued and outstanding as of April 17, 2023, as reported by the Issuer in its Current Report on Form 8-K, filed on June 13, 2023 (as adjusted for the Reverse Stock Split), (ii) 27,874 shares of Class A Common Stock issuable in connection with the Series I Warrants and Series II Warrants and (iii) 730,166 shares of Class A Common Stock issuable upon conversion of Notes.

     

     

     

    Item 1. Security and Issuer

     

    This Statement on Schedule 13D relates to the Class A Common Stock, par value $0.0001 per share (the “Class A Common Stock” or the “Shares”) of ATI Physical Therapy, Inc., a Delaware corporation (the “Issuer” or the “Company”). The address of the Issuer’s principal executive office is 790 Remington Boulevard, Boilingbrook, Illinois 60440.

     

    Item 2. Identity and Background

     

    (a)This Statement is being jointly filed by each of the following persons (each a “Reporting Person” and, collectively, the “Reporting Persons”) pursuant to Rule 13d-1(k) promulgated by the Securities and Exchange Commission (the “SEC”) pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”):

     

    a.Onex Corporation, an Ontario corporation (“Onex”), the sole shareholder of OMI Partnership Holdings Ltd.;

     

    b.OMI Partnership Holdings Ltd., an Ontario corporation (“OMI Partnership Holdings”), the sole member of Onex Capital Solutions GP, LLC;

     

    c.Onex Capital Solutions GP, LLC, a Delaware limited liability company (“OCS GP, LLC”), the general partner of Onex Capital Solutions GP, LP;

     

    d.Onex Capital Solutions GP, LP, a Delaware limited partnership (“OCS GP, LP”), the general partner of Onex Capital Solutions Holdings, LP;

     

    e.Onex Capital Solutions Holdings, LP, a Delaware limited partnership (“OCS”); and

     

    f.Gerald W. Schwartz, the Chairman of Onex.

     

    Information with respect to each of the Reporting Persons is given solely by such Reporting Person, and no Reporting Person assumes responsibility for the accuracy or completeness of information by another Reporting Person. A Joint Filing Agreement among the Reporting Persons is attached hereto as Exhibit 99.1.

     

    This Schedule 13D relates to the Series I Warrants, Series II Warrants and Notes held of record by OCS. Onex Corporation may be deemed to beneficially own the shares of Class A Common Stock held by OCS, through its ownership of all of the equity of OMI Partnership Holdings Ltd., which is the sole member of OCS GP, LLC, which is the general partner of OCS GP, LP, which is the general partner of OCS. Mr. Schwartz, the Chairman of Onex Corporation, indirectly owns shares representing a majority of the voting rights of the shares of Onex Corporation, and as such may be deemed to beneficially own all of the shares of Class A Common Stock beneficially owned by Onex Corporation. Mr. Schwartz disclaims any such beneficial ownership.

     

    (b)The principal business and principal office address of the Reporting Persons is c/o Onex Corporation, 161 Bay Street P.O. Box 700, Toronto, ON, Canada, M5J 2S1.

     

    (c)Set forth in Schedule A attached hereto and incorporated herein by reference is a list of the persons required to be identified in respect of the Reporting Persons pursuant to General Instruction C to Schedule 13D (collectively, the “Covered Persons”), and the business address and present principal occupation of each of the Covered Persons.

     

    (d)During the past five years, none of the Reporting Persons and, to the best of the Reporting Persons’ knowledge, none of the Covered Persons, has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e)During the past five years, none of the Reporting Persons and, to the best of the Reporting Persons’ knowledge, none of the Covered Persons, was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which such person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    (f)The jurisdictions in which the other Reporting Persons were formed are set forth in Item 2(a), and such information is incorporated herein by reference.

     

     

     

    Item 3. Source and Amount of Funds or Other Consideration.

     

    The information set forth or incorporated by reference in Item 6 of this Statement is incorporated by reference into this Item 3. As described in Item 6 of this Statement, the Notes were acquired in connection with the Transaction.

     

    On February 24, 2022 (the “Preferred Financing Closing Date”), the Company entered into a Series A Senior Preferred Stock Purchase Agreement (“Purchase Agreement”) with the purchasers signatory thereto (including certain of the Reporting Persons, the “Preferred Equityholders”), pursuant to which the Preferred Equityholders purchased from the Company, in the aggregate, 165,000 shares of Series A Senior Preferred Stock with an initial stated value of $1,000 per share, or $165,000,000 of stated value in the aggregate (“Series A Senior Preferred Stock” and such transaction, the “Preferred Stock Financing”). In connection with the Preferred Stock Financing, the Company agreed to issue to certain of the Reporting Persons: (i) warrants (the “Series I Warrants”) entitling such Reporting Persons to purchase, 13,240 Shares at an exercise price equal to $150.00 (each as adjusted for the 1-for-50 reverse stock split of the Company effective as of June 14, 2023, as reported by the Issuer in its Current Report on Form 8-K, filed on June 14, 2023 (the “Reverse Stock Split”)), subject to adjustment, exercisable for a five-year period from the Preferred Financing Closing Date; and (ii) warrants (the “Series II Warrants” and together with the Series I Warrants, the “Warrants”) entitling such Reporting Persons to purchase 14,634 Shares at an exercise price equal to $0.50 (each as adjusted for the Reverse Stock Split), subject to adjustment, exercisable for a five-year period from the Preferred Financing Closing Date. Such number of shares of Shares purchasable pursuant to the Warrants (the “Warrant Shares”) may be adjusted from time to time as set forth in the Warrant Agreement (as defined below). The Company has entered into a Warrant Agreement with Continental Stock Transfer & Trust Company, as warrant agent, as of the Preferred Financing Closing Date (the “Warrant Agreement”). Under the terms of the Warrant Agreement, the Preferred Equityholders are entitled to, among other things, registration rights with respect to the Warrant Shares, anti-dilution protection (subject to customary carve-outs) and pre-emptive rights.

     

    In connection with the Preferred Stock Financing, certain of the Reporting Persons paid an aggregate total of $19,800,000 for 20,000 shares of Series A Senior Preferred Stock and received the Series I Warrants and Series II Warrants reported herein. As described in Item 6 below, certain of the Reporting Persons (x) exchanged an aggregate total of $8,840,357.39 of principal amount of term loans held by such Reporting Persons under the 2022 Credit Agreement for Notes and (y) purchased an additional $286,719.49 of Notes in consideration of interest paid or payable under the 2022 Credit Agreement through the Closing Date pursuant to the First Amendment to the Note Purchase Agreement (as such undefined terms are defined in Item 6 below).

     

    Item 4. Purpose of Transaction.

     

    The information set forth in or incorporated by reference in Item 3 above and Item 6 below is incorporated into this Item 4 by reference.

     

    The Reporting Persons acquired beneficial ownership of the Shares for investment purposes because they believed the Shares represented an attractive investment opportunity. Consistent with their investment intent, the Reporting Persons may engage in communications with, without limitation, one or more shareholders of the Issuer, one or more officers of the Issuer and/or one or more members of the Issuer’s board of directors (the “Board”) regarding the Issuer, including but not limited to its operations, governance and control.

     

    Except as otherwise set forth in this Item 4, Item 6 and elsewhere in this Schedule 13D, the Reporting Persons do not have any present plans or proposals that relate to or would result in any of the actions specified in clauses (a) through (j) of the instructions to Item 4 of Schedule 13D. Notwithstanding the foregoing, the Reporting Persons specifically reserve the right to change their intention with respect to any or all of such matters. In reaching any decision as to their course of action (as well as to the specific elements thereof), the Reporting Persons currently expect that they would take into consideration a variety of factors, including, but not limited to, the following: the Issuer’s business and prospects; other developments concerning the Issuer and its businesses generally; other business opportunities available to the Reporting Persons; developments with respect to the business of the Reporting Persons; changes in law and government regulations; general economic conditions; and money and stock market conditions, including the market price of the securities of the Issuer

     

    Item 5. Interest in Securities of the Issuer.

     

    (a)—(b) The information relating to the beneficial ownership of the Shares by each of the Reporting Persons set forth in Rows 7 through 13 on each of the cover pages hereto is incorporated by reference herein and is as of the date hereof. Such information is based on 4,169,911 shares of Class A Common Stock issued and outstanding as of April 17, 2023, as reported by the Issuer in its Current Report on Form 8-K, filed on June 13, 2023 (as adjusted for the Reverse Stock Split).

     

     

     

    By virtue of the relationship among the Reporting Persons described in Item 2, each such Reporting Person may be deemed to share the power to vote or direct the vote and to share the power to dispose of or direct the disposition of the Shares as set forth in rows 7 through 13 of the cover pages of this Statement. The filing of this Statement shall not be construed as an admission that any such Reporting Person or any Covered Person is, for the purpose of Section 13(d) or 13(g) of the Exchange Act, the beneficial owner of any securities covered by this Statement.

     

    As a result of the agreements made pursuant to the TSA (as defined and described in Item 6 of this Schedule 13D), the Reporting Persons may be deemed to constitute a “group” within the meaning of Section 13(d)(3) of Exchange Act. This Schedule 13D shall not be construed as an admission by the Reporting Persons that the Reporting Persons are, for the purposes of Section 13(d) of the Exchange Act, the beneficial owners of any shares of Class A Common Stock covered by the agreements made pursuant to the TSA unless otherwise expressly stated herein.

     

    (c)       Except as otherwise set forth in this Statement, none of the Reporting Persons has effected any transactions in the Class A Common Stock during the past 60 days.

     

    (d)       Except as stated within this Item 5, to the knowledge of the Reporting Persons, only the Reporting Persons have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, the Class A Common Stock of the Issuer reported by this Schedule 13D.

     

    (e)       Inapplicable.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

     

    The information set forth or incorporated by reference in Item 4 of this Statement is incorporated by reference into this Item 6.

     

    Transaction Support Agreement

     

    On April 17, 2023, the Company entered into an Amended and Restated Transaction Support Agreement (the “TSA”) with certain of its first lien lenders under that certain Credit Agreement, dated as of February 24, 2022 (as amended, the “2022 Credit Agreement”) by and among, inter alios, ATI Holdings Acquisition, Inc., an indirect subsidiary of the Company and as borrower (“Opco”), Wilco Intermediate Holdings, Inc. (“Holdings”), the lenders from time to time party thereto, the lender representative and the administrative agent; the administrative agent under the 2022 Credit Agreement; the Preferred Equityholders; and holders of the majority of the Shares (together with the First Lien Lenders and the Preferred Equityholders, the “Parties”), setting forth the principal terms of a comprehensive transaction to enhance the Company’s liquidity (the “Transaction”). Pursuant to the TSA, the Company agreed to a delayed draw new money financing in which the Company (i) may cause to be issued to the Purchasers (including OCS) an aggregate principal amount of $25.0 million in the form of a new stapled security, comprised of (A) second lien PIK convertible notes (the “Notes”) and (B) shares of Series B Preferred Stock (as defined below), (ii) facilitated the exchange of $100.0 million of the aggregate principal amount of the term loans under the 2022 Credit Agreement held by certain of the Preferred Equityholders (including OCS) for Notes and Series B Preferred Stock as described below and (iii) agreed to certain other changes to the terms of the 2022 Credit Agreement, including modifications of the financial covenants thereunder. Holders of the Notes will also receive additional Notes upon the in-kind payment of interest on any outstanding Notes. The Notes are convertible into Shares at a fixed conversion price of $12.50 (as adjusted for the Reverse Stock Split and subject to adjustment as provided in the Note Purchase Agreement (as defined below)).

     

    On June 15, 2023 (the “Closing Date”), the Company completed the Transaction, which was approved by the Company’s stockholders at the Company’s annual meeting of stockholders held on June 13, 2023. On the Closing Date, certain previously executed agreements became effective, including (i) Amendment No. 2 to the 2022 Credit Agreement (the “Credit Agreement Amendment”), by, among others, Opco, Holdings, Barclays Bank PLC, as administrative agent and issuing bank (the “Administrative Agent”), and the lenders party thereto (including certain of the Reporting Persons), which amends the 2022 Credit Agreement, (ii) a Second Lien Note Purchase Agreement (the “Original Note Purchase Agreement”), by, among others, the Company, Wilco Holdco, Inc. (“Wilco”), Holdings, Opco, the purchasers from time to time party thereto (including OCS, the “Purchasers”) and Wilmington Savings Fund Society, FSB, as purchaser representative (the “Purchaser Representative”) and (iii) certain other definitive agreements relating to the Transaction (such documents referred to collectively as the “Signing Date Definitive Documents”).

     

     

     

    In addition, on the Closing Date, the Company entered into or filed with the Secretary of State of the State of Delaware, as applicable, certain other agreements (collectively, the “Closing Date Definitive Documents”) to implement certain terms of the TSA. The Closing Date Definitive Documents include (i) the First Amendment to Note Purchase Agreement (together with the Original Note Purchase Agreement, the “Note Purchase Agreement”), dated as of the Closing Date, by and among the Company, Wilco, Holdings, Opco, the Purchasers party thereto (in such capacity, the “First Amendment Purchasers”, which includes OCS)) and the Purchaser Representative, pursuant to which the First Amendment Purchasers agreed to purchase, and the Company agreed to issue, an additional $3,243,302.02 aggregate principal amount of Notes (including $286,719.49 to OCS), (ii) the Consent to Amendment No. 2 to Credit Agreement, dated as of the Closing Date, by, among others, Opco, Holdings, the lenders party thereto and the Administrative Agent, which amends the Credit Agreement Amendment, (iii) the First Amended and Restated Certificate of Designation of Series A Senior Preferred Stock of the Company, dated as of June 15, 2023 (the “A&R Series A COD”), which, as agreed under the TSA, (A) revised the Preferred Equityholders’ preexisting rights to designate and elect one director to the Board to provide that the Preferred Equityholders have the right to appoint three additional directors to the Board (resulting in the right of the Preferred Equityholders to appoint a total of four directors to the Board) until such time after the Closing Date that the Lead Purchaser (in each case, as defined in certain of the transaction agreements entered into in connection with the original issuance of the Series A Senior Preferred Stock) ceases to hold at least 50.1% of the Series A Preferred Senior Stock held by it as of the Closing Date, and (B) removed the provision that eliminated the Preferred Equityholders’ director designation rights upon the Company’s achievement of certain amounts of EBITDA; (iv) the First Amendment to that certain Investors’ Rights Agreement (as amended, the “Investors’ Rights Agreement”), dated as of February 24, 2022, by and among the Company and the Preferred Equityholders listed therein, which made changes similar to those under the A&R Series A COD and further provided that (A) all designee directors of the Preferred Equityholders will be subject to consideration by the Board (acting in good faith and consistent with their review of other Board candidates) and (B) at least one director appointed in accordance with the A&R Series A COD be unaffiliated with (and independent of) the Preferred Equityholders and meet the definition of “independent” under the listing standards of the New York Stock Exchange, and by the Securities and Exchange Commission; (v) the Certificate of Designation of Series B Preferred Stock of the Company, dated as of June 15, 2023 (the “Series B COD”), which Series B Preferred Stock is further described below, (vi) the Registration Rights Agreement, dated as of June 15, 2023, by and among the Company and the Purchasers with respect to the resale of shares of Common Stock into which the Notes are convertible; and (vii) such other related documents and ancillary agreements required to implement the Transaction.

     

    Issuance of New Second Lien PIK Convertible Notes and Series B Preferred Stock

     

    On the Closing Date, pursuant to the Note Purchase Agreement and the other Signing Date Definitive Documents, the Company (i) exchanged $100.0 million of the aggregate principal amount of the term loans under the 2022 Credit Agreement held by certain of the Preferred Equityholders for $100.0 million aggregate principal amount of a new stapled security, comprised of (A) Notes and (B) shares of Series B Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock”), which provide the holder thereof with voting rights such that the holders thereof have the right to vote on corporate matters on an as-converted basis as if the conversion occurred at an initial price per share equal to $12.87, and (ii) issued to the First Amendment Purchasers, and the First Amendment Purchasers purchased from the Company, an aggregate principal amount of $3,243,302.02 million in Notes and shares of stapled Series B Preferred Stock.

     

    This discussion of the Transaction does not purport to be complete and is qualified in its entirety by reference to the Signing Date Definitive Documents and Closing Date Definitive Documents, which are further described in and certain of which are filed as exhibits to this Schedule 13D and incorporated herein by reference.

     

     

     

    Item 7. Material to be Filed as Exhibits

     

    Exhibit No.   Description
    1   Warrant Agreement (including form of Warrant as Exhibit A thereto) (filed as Exhibit 4.1 to the Issuer’s Current Report on Form 8-K filed on February 25, 2022 and incorporated herein by reference).
    2   Amended and Restated Transaction Support Agreement (filed as Exhibit 10.1 to the Issuer’s Current Report on Form 8-K filed on April 21, 2023 and incorporated herein by reference).
    3   Second Lien Note Purchase Agreement (filed as Exhibit 10.3 to the Issuer’s Current Report on Form 8-K filed on April 21, 2023 and incorporated herein by reference).
    4   Amendment No. 2 to the Credit Agreement (filed as Exhibit 10.2 to the Issuer’s Current Report on Form 8-K filed on April 21, 2023 and incorporated herein by reference).
    5   First Amendment to Note Purchase Agreement (filed as Exhibit 10.7 to the Issuer’s Current Report on Form 8-K filed on June 15, 2023 and incorporated herein by reference).
    6   Consent to Amendment No. 2 to Credit Agreement (filed as Exhibit 10.3 to the Issuer’s Current Report on Form 8-K filed on June 15, 2023 and incorporated herein by reference).
    7   First Amended and Restated Certificate of Designation of Series A Senior Preferred Stock of the Company (filed as Exhibit 3.1 to the Issuer’s Current Report on Form 8-K filed on June 15, 2023 and incorporated herein by reference).
    8   First Amendment to the Investors’ Rights Agreement (filed as Exhibit 10.5 to the Issuer’s Current Report on Form 8-K filed on June 15, 2023 and incorporated herein by reference).
    9   Certificate of Designation of Series B Preferred Stock of the Company (filed as Exhibit 3.2 to the Issuer’s Current Report on Form 8-K filed on June 15, 2023 and incorporated herein by reference).
    10   Registration Rights Agreement (filed as Exhibit 10.6 to the Issuer’s Current Report on Form 8-K filed on June 15, 2023 and incorporated herein by reference).
    99.1   Joint Filing Agreement among the Reporting Persons, dated as of June 26, 2023.
    99.2   Power of Attorney incorporated by reference to Exhibit 99.3 to Amendment No. 1 to Schedule 13G filed with the Securities and Exchange Commission with respect to Fly Leasing Limited on April 3, 2017.

     

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Date: June 26, 2023

     

      ONEX CORPORATION
       
      By: /s/ Andrea E. Daly
        Name: Andrea E. Daly
        Title:    Managing Director – General Counsel
       
       
     

    OMI PARTNERSHIP HOLDINGS LTD.

       
      By: /s/ Steve Gutman
        Name: Steve Gutman
        Title:    Authorized Signatory
       
       
      ONEX CAPITAL SOLUTIONS GP, LLC
       
      By: /s/ Steve Gutman
        Name: Steve Gutman
        Title:    General Counsel
       
       
     

    ONEX CAPITAL SOLUTIONS GP, LP

     

    By: Onex Capital Solutions GP, LLC, its general partner

       
      By: /s/ Steve Gutman
        Name: Steve Gutman
        Title:   General Counsel
       
       
     

    ONEX CAPITAL SOLUTIONS HOLDINGS, LP

     

    By: Onex Capital Solutions GP, LP, its general partner

     

    By: Onex Capital Solutions GP, LLC, its general partner

       
      By: /s/ Steve Gutman
        Name: Steve Gutman
        Title:    General Counsel
       
       
      GERALD W. SCHWARTZ
       
      By: /s/ Andrea E. Daly
        Name: Andrea Daly
        Title:    Attorney-in-fact

     

     

    SCHEDULE A

     

    The name, business address, title, present principal occupation or employment of each of the directors and executive officers of Onex Corporation (“Onex”), OMI Partnership Holdings Ltd. (“OMI Partnership Holdings”) and Onex Capital Solutions GP, LLC (“OCS GP, LLC”) are set forth below. If no business address is given, the director’s or executive officer’s business address is 161 Bay Street, Toronto, ON M5J 2S1, Canada.

     

    Onex Corporation

     

    Name Present Principal Occupation or Employment Citizenship
    Gerald W. Schwartz Chairman of the Board, Director Canada
    Robert M. LeBlanc Chief Executive Officer and President, Director United States of America
    Ewout R. Heersink Vice Chair, Director Canada
    Lisa Carnoy Director United States of America
    Mitchell Goldhar Director Canada
    John B. McCoy Director United States of America
    Sarabjit S. Marwah Director Canada
    J. Robert S. Prichard Director Canada
    Heather M. Reisman Director Canada
    Arni C. Thorsteinson Director Canada
    Beth A. Wilkinson Director United States of America
    Anthony Munk Vice Chair Canada
    Christopher A. Govan Senior Managing Director – Chief Financial Officer Canada
    David Copeland Managing Director – Finance Canada
    Andrea E. Daly Managing Director – General Counsel Canada

     

    OMI Partnership Holdings Ltd.

     

    Name Present Principal Occupation or Employment Citizenship
    Colin Sam Director Canada
    Derek MacKay Vice President Canada
    Christopher A. Govan President Canada
    David Copeland Vice President, Director Canada
    Andrea E. Daly Secretary Canada

     

    Onex Capital Solutions GP, LLC

     

    Name Present Principal Occupation or Employment Citizenship
    Steve Gutman General Counsel United States of America

     

     

     

    Get the next $ATIP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATIP

    DatePrice TargetRatingAnalyst
    10/27/2022$2.00 → $1.14Buy → Hold
    Jefferies
    4/6/2022$2.00Hold
    Deutsche Bank
    3/4/2022$4.00Hold → Buy
    The Benchmark Company
    1/14/2022$3.50 → $5.00Hold → Buy
    Jefferies
    1/10/2022$5.00 → $3.50Neutral
    Citigroup
    7/27/2021Outperform → Mkt Perform
    Barrington Research
    7/27/2021Buy → Hold
    Benchmark
    7/27/2021Buy → Hold
    The Benchmark Company
    More analyst ratings

    $ATIP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Parisi James E. bought $50,180 worth of shares (52,000 units at $0.96), increasing direct ownership by 120% to 95,356 units (SEC Form 4) (Amendment)

    4/A - ATI Physical Therapy, Inc. (0001815849) (Issuer)

    2/23/24 1:17:52 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    $ATIP
    SEC Filings

    View All

    SEC Form 10-K filed by ATI Physical Therapy Inc.

    10-K - ATI Physical Therapy, Inc. (0001815849) (Filer)

    3/18/25 4:10:24 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    SEC Form 15-12G filed by ATI Physical Therapy Inc.

    15-12G - ATI Physical Therapy, Inc. (0001815849) (Filer)

    3/17/25 11:20:31 AM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    SEC Form EFFECT filed by ATI Physical Therapy Inc.

    EFFECT - ATI Physical Therapy, Inc. (0001815849) (Filer)

    3/17/25 12:15:04 AM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    $ATIP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ATI Physical Therapy downgraded by Jefferies with a new price target

    Jefferies downgraded ATI Physical Therapy from Buy to Hold and set a new price target of $1.15 from $2.00 previously

    10/27/22 9:10:52 AM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    Deutsche Bank initiated coverage on ATI Physical Therapy with a new price target

    Deutsche Bank initiated coverage of ATI Physical Therapy with a rating of Hold and set a new price target of $2.00

    4/6/22 7:05:46 AM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    ATI Physical Therapy upgraded by The Benchmark Company with a new price target

    The Benchmark Company upgraded ATI Physical Therapy from Hold to Buy and set a new price target of $4.00

    3/4/22 7:01:48 AM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    $ATIP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Vitti Sharon covered exercise/tax liability with 1,611 shares, decreasing direct ownership by 2% to 84,305 units (SEC Form 4)

    4 - ATI Physical Therapy, Inc. (0001815849) (Issuer)

    5/14/25 4:58:21 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    Interim CFO Rundell Scott covered exercise/tax liability with 707 shares, decreasing direct ownership by 12% to 4,995 units (SEC Form 4)

    4 - ATI Physical Therapy, Inc. (0001815849) (Issuer)

    3/25/25 5:42:52 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    Chief Executive Officer Vitti Sharon covered exercise/tax liability with 10,026 shares, decreasing direct ownership by 10% to 85,916 units (SEC Form 4)

    4 - ATI Physical Therapy, Inc. (0001815849) (Issuer)

    3/25/25 5:36:56 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    $ATIP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ATI Physical Therapy Recognized for Commitment to Safety in Use of Dry Needling

    'NeedleCert PrivilegePath' drives exceptional learner adoption and clinical consistency DOWNERS GROVE, Ill., Sept. 25, 2025 /PRNewswire/ -- ATI Physical Therapy, a nationally recognized provider of outpatient physical therapy and rehabilitation services, has been named the winner of the Best Training Adoption Award in Absorb Software's 2025 Absorbies Awards, which recognizes visionary individuals and organizations that are reshaping learning and development (L&D) through creativity, measurable impact, and inclusive excellence. The 2025 Absorbies drew a record 122 nominations f

    9/25/25 3:39:00 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    ATI Physical Therapy Goes Private

    ATI Physical Therapy Transitions from Public to Private OwnershipMove to Private Ownership Supports Long-Term Growth, Operational Flexibility, and Continued Focus on Patient Care DOWNERS GROVE, Ill., Aug. 1, 2025 /PRNewswire/ -- ATI Physical Therapy, Inc. ("ATI") (OTC:ATIP), a nationally recognized provider of outpatient physical therapy and rehabilitation services, today announced that a consortium of existing stockholders, holding over 90% of the voting shares and led by private investment firms, Knighthead Capital Management and Marathon Asset Management, completed a merger to take the company private. As a result of the merger, shares not held by this group of stockholders will be acquir

    8/1/25 10:35:00 AM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    ATI Physical Therapy Closes $26 Million 8% Second Lien PIK Convertible Note Financing

    DOWNERS GROVE, Ill., March 4, 2025 /PRNewswire/ -- ATI Physical Therapy, Inc. (OTC:ATIP) ("ATI" or the "Company"), a nationally recognized outpatient physical therapy provider in the United States, announced today that on March 3, 2025, it closed a $26 million 8% second lien PIK convertible note financing. "This new financing is a critical step in fortifying our financial foundation and positioning us to execute on our strategic vision," said Sharon Vitti, Chief Executive Officer. Pursuant to the financing, the Company issued to certain of its existing preferred equity holders

    3/4/25 8:35:00 AM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    $ATIP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by ATI Physical Therapy Inc.

    SC 13D/A - ATI Physical Therapy, Inc. (0001815849) (Subject)

    12/17/24 5:51:04 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    Amendment: SEC Form SC 13D/A filed by ATI Physical Therapy Inc.

    SC 13D/A - ATI Physical Therapy, Inc. (0001815849) (Subject)

    12/2/24 4:57:34 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    Amendment: SEC Form SC 13D/A filed by ATI Physical Therapy Inc.

    SC 13D/A - ATI Physical Therapy, Inc. (0001815849) (Subject)

    11/25/24 8:12:55 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    $ATIP
    Financials

    Live finance-specific insights

    View All

    ATI Physical Therapy Receives Delisting Notice From the New York Stock Exchange

    BOLINGBROOK, Ill., Dec. 3, 2024 /PRNewswire/ -- ATI Physical Therapy, Inc. (NYSE:ATIP) ("ATI" or the "Company"), a nationally recognized outpatient physical therapy provider in the United States, today announced that it received notification from the New York Stock Exchange ("NYSE") indicating that the Company's Class A common stock will be delisted, and trading of its Class A common stock on the NYSE was suspended, after market close on December 3, 2024. The Company today also announced that it is currently in discussions to obtain interim financing in an effort to provide a near-term opportunity for the Company's common stockholders to obtain liquidity.

    12/3/24 4:55:00 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    ATI Physical Therapy to Announce Third Quarter 2024 Financial Results

    BOLINGBROOK, Ill., Oct. 21, 2024 /PRNewswire/ -- ATI Physical Therapy, Inc. – ("ATI" or the "Company") (NYSE:ATIP), a nationally recognized outpatient physical therapy provider in the United States, today announced that it will release third quarter 2024 financial results on Monday, November 4, 2024, after the market closes. In conjunction, the company will host a conference call to review results at 5 p.m. ET on the same day. Conference Call Details Management will host a conference call at 5 p.m. Eastern Time on November 4, 2024, to review third quarter 2024 financial result

    10/21/24 12:00:00 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    ATI Physical Therapy to Announce Second Quarter 2024 Financial Results

    BOLINGBROOK, Ill., July 26, 2024 /PRNewswire/ -- ATI Physical Therapy, Inc. – ("ATI" or the "Company") (NYSE:ATIP), a nationally recognized outpatient physical therapy provider in the United States, today announced that it will release second quarter 2024 financial results on Monday, August 5, 2024, after the market closes. In conjunction, the company will host a conference call to review results at 5 p.m. ET on the same day. Conference Call Details Management will host a conference call at 5 p.m. Eastern Time on August 5, 2024, to review second quarter 2024 financial results.

    7/26/24 3:13:00 PM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    $ATIP
    Leadership Updates

    Live Leadership Updates

    View All

    ATI PHYSICAL THERAPY REOPENS IN NEW KIRKLAND LOCATION

    The new larger facility signals ATI's enhanced access to care in Washington BOLINGBROOK, Ill., Feb. 20, 2024 /PRNewswire/ -- ATI Physical Therapy ("ATI" or the "Company") (NYSE:ATIP), a nationally recognized outpatient physical therapy provider in the United States, proudly announces the relocation of its Kirkland, Wash. clinic to a new state-of the-art facility on 97th Lane in Kirkland. This move signifies ATI's commitment to delivering exceptional physical therapy services while catering to the needs of the Greater Kirkland and neighboring areas. In collaboration with The Gr

    2/20/24 9:00:00 AM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    ATI PHYSICAL THERAPY LAUNCHES THE INSTITUTE FOR MUSCULOSKELETAL ADVANCEMENT (iMSKA)

    iMSKA's purpose is to drive musculoskeletal research and advance post-secondary education in the field; applications for iMSKA fellowships and residencies forthcoming BOLINGBROOK, Ill., Feb. 13, 2024 /PRNewswire/ -- ATI Physical Therapy ("ATI" or the "Company") (NYSE:ATIP), a nationally recognized outpatient physical therapy provider in the United States, today announced the formation of The Institute for Musculoskeletal Advancement (iMSKA). iMSKA represents a commitment to advance scientific MSK research while providing resources and opportunities for practicing professionals.

    2/13/24 9:00:00 AM ET
    $ATIP
    Hospital/Nursing Management
    Health Care

    ATI PHYSICAL THERAPY INAUGURATES 40TH LOCATION IN MASSACHUSETTS

    Physical therapy provider now servicing patients in Greater Lynn County BOLINGBROOK, Ill., Dec. 12, 2023 /PRNewswire/ -- ATI Physical Therapy ("ATI" or the "Company") (NYSE:ATIP), a nationally recognized outpatient physical therapy provider in the United States, proudly unveils its latest clinic in Massachusetts, marking its 40th clinic in the state. Situated in Swampscott, this new location is committed to delivering high-quality physical therapy services to Greater Lynn County residents and neighboring communities, fostering accessibility and excellence in helping patients live their best, most active lives.

    12/12/23 9:00:00 AM ET
    $ATIP
    Hospital/Nursing Management
    Health Care